Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease

Neuropharmacology

Volumn 136, Issue , 2018, Pages 260-270

  Athauda, Dilan ^a   Foltynie, Thomas ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Exenatide; Glucagon like peptide 1 agonist; Insulin resistance; Neuroprotection; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GENIPOSIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; LEVODOPA; METFORMIN; PLACEBO; SULFONYLUREA; NEUROPROTECTIVE AGENT;

APOPTOSIS; CLINICAL STUDY; DISEASE ASSOCIATION; DRUG MECHANISM; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SIGNALING; NERVE CELL PLASTICITY; NEURITE OUTGROWTH; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; AGONISTS; ANIMAL; METABOLISM;

ANIMALS; EXENATIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 85030707291     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2017.09.023     Document Type: Review

References (141)

1. Abuirmeileh, A., Harkavyi, A., Rampersaud, N., Lever, R., Tadross, J.A., Bloom, S.R., Whitton, P.S., Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat. J. Pharm. Pharmacol. 64 (2012), 637–643, 10.1111/j.2042-7158.2011.01394.x.
2. Alismail, H., Jin, S., Microenvironmental stimuli for proliferation of functional islet β-cells. Cell Biosci., 4, 2014, 12, 10.1186/2045-3701-4-12.
3. Alvarez, E., Martínez, M.D., Roncero, I., Chowen, J.A., García-Cuartero, B., Gispert, J.D., Sanz, C., Vázquez, P., Maldonado, A., de Cáceres, J., Desco, M., Pozo, M.A., Blázquez, E., The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J. Neurochem. 92 (2005), 798–806, 10.1111/j.1471-4159.2004.02914.x.
4. Arnold, S.E., Lucki, I., Brookshire, B.R., Carlson, G.C., Browne, C.A., Kazi, H., Bang, S., Choi, B.-R., Chen, Y., McMullen, M.F., Kim, S.F., High fat diet produces brain insulin resistance, synaptodendritic abnormalities and altered behavior in mice. Neurobiol. Dis. 67 (2014), 79–87, 10.1016/j.nbd.2014.03.011.
5. Ashpole, N.M., Sanders, J.E., Hodges, E.L., Yan, H., Sonntag, W.E., Growth hormone, insulin-like growth factor-1 and the aging brain. Exp. Gerontol. 68 (2015), 76–81, 10.1016/j.exger.2014.10.002.
6. Athauda, D., Foltynie, T., Insulin resistance and Parkinson's disease: a new target for disease modification?. Prog. Neurobiol., 2016, 10.1016/j.pneurobio.2016.10.001.
7. Athauda, D., Foltynie, T., The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. Drug Discov. Today 21 (2016), 802–818, 10.1016/j.drudis.2016.01.013.
8. Athauda, D., Foltynie, T., The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nat. Rev. Neurol. 11 (2014), 25–40, 10.1038/nrneurol.2014.226.
9. Athauda, D., Maclagan, K., Skene, S.S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., Li, Y., Aviles-Olmos, I., Warner, T.T., Limousin, P., Lees, A.J., Greig, N.H., Tebbs, S., Foltynie, T., Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet, 2017, 10.1016/S0140-6736(17)31585-4.
10. Athauda, D., Wyse, R., Brundin, P., Foltynie, T., Is exenatide a treatment for Parkinson's disease?. J. Park. Dis. 7 (2017), 451–458, 10.3233/JPD-171192.
11. Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., Limousin, P., Foltynie, T., Exenatide and the treatment of patients with Parkinson ‘s disease, 123, 2013, 10.1172/JCI68295.2730.
12. Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Kahan, J., Fmedsci, P.E., Whitton, P., Wyse, R., Isaacs, T., Lees, A., Limousin, P., Foltynie, T., Motor and cognitive advantages persist 12 Months after exenatide exposure in Parkinson's disease. J. Park. Dis., 2014, 10.3233/JPD-140364.
13. Aviles-Olmos, I., Limousin, P., Lees, A., Foltynie, T., Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain 136 (2013), 374–384, 10.1093/brain/aws009.
14. Baggio, L.L., Drucker, D.J., Biology of incretins: GLP-1 and GIP. Gastroenterology 132 (2007), 2131–2157, 10.1053/j.gastro.2007.03.054.
15. Baladi, M.G., Horton, R.E., Owens, W.A., Daws, L.C., France, C.P., Eating high fat chow decreases dopamine clearance in adolescent and adult male rats but selectively enhances the locomotor stimulating effects of cocaine in adolescents. Int. J. Neuropsychopharmacol., 18, 2015, pyv024, 10.1093/ijnp/pyv024.
16. Bao, Y., Jiang, L., Chen, H., Zou, J., Liu, Z., Shi, Y., The neuroprotective effect of liraglutide is mediated by glucagon-like peptide 1 receptor-mediated activation of cAMP/PKA/CREB pathway. Cell. Physiol. Biochem. 36 (2015), 2366–2378, 10.1159/000430199.
17. Baskin, D.G., Wilcox, B.J., Figlewicz, D.P., Dorsa, D.M., Insulin and insulin-like growth factors in the CNS. Trends Neurosci. 11 (1988), 107–111.
18. Bassil, F., Canron, M.-H., Vital, A., Bezard, E., Li, Y., Greig, N.H., Gulyani, S., Kapogiannis, D., Fernagut, P.-O., Meissner, W.G., Insulin resistance and exendin-4 treatment for multiple system atrophy. Brain 140 (2017), 1420–1436, 10.1093/brain/awx044.
19. Bassil, F., Fernagut, P.-O., Bezard, E., Meissner, W.G, Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Prog. Neurobiol 118 (2014 Jul), 1–18, 10.1016/j.pneurobio.2014.02.005 [Epub 2014 Feb 28].
20. Béraud, D., Hathaway, H.A., Trecki, J., Chasovskikh, S., Johnson, D.A., Johnson, J.A., Federoff, H.J., Shimoji, M., Mhyre, T.R., Maguire-Zeiss, K.A., Microglial activation and antioxidant responses induced by the Parkinson's disease protein α-synuclein. J. Neuroimmune Pharmacol. 8 (2013), 94–117, 10.1007/s11481-012-9401-0.
21. Bergenstal, R.M., Wysham, C., Macconell, L., Malloy, J., Walsh, B., Yan, P., Wilhelm, K., Malone, J., Porter, L.E., Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 376 (2010), 431–439, 10.1016/S0140-6736(10)60590-9.
22. Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Rönnholm, H., Wikström, L., Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J. Neurosci. Res. 86 (2008), 326–338, 10.1002/jnr.21483.
23. Blandini, F., Neural and immune mechanisms in the pathogenesis of Parkinson's disease. J. Neuroimmune Pharmacol. 8 (2013), 189–201, 10.1007/s11481-013-9435-y.
24. Brauer, R., Bhaskaran, K., Chaturvedi, N., Dexter, D.T., Smeeth, L., Douglas, I., Glitazone treatment and incidence of Parkinson's disease among people with diabetes: a retrospective cohort study. PLoS Med., 12, 2015, e1001854, 10.1371/journal.pmed.1001854.
25. Buse, J.B., Rosenstock, J., Sesti, G., Schmidt, W.E., Montanya, E., Brett, J.H., Zychma, M., Blonde, L., LEAD-6 study group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet (London, England) 374 (2009), 39–47, 10.1016/S0140-6736(09)60659-0.
26. Carro, E., Trejo, J.L., Gomez-Isla, T., LeRoith, D., Torres-Aleman, I., Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat. Med. 8 (2002), 1390–1397, 10.1038/nm793.
27. Cereda, E., Barichella, M., Cassani, E., Caccialanza, R., Pezzoli, G., Clinical features of Parkinson disease when onset of diabetes came first: a case-control study. Neurology 78 (2012), 1507–1511, 10.1212/WNL.0b013e3182553cc9.
28. Chen, S., An, F.-M., Yin, L., Liu, A.-R., Yin, D.-K., Yao, W.-B., Gao, X.-D., Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation. Neuroscience 256 (2014), 137–146, 10.1016/j.neuroscience.2013.10.038.
29. Chen, S., Liu, A., An, F., Yao, W., Gao, X., Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4. Age (Dordr) 34 (2012), 1211–1224, 10.1007/s11357-011-9303-8.
30. Chen, Y., Zhang, Y., Li, L., Hölscher, C., Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease. Eur. J. Pharmacol., 2015, 10.1016/j.ejphar.2015.09.029.
31. Cheng, Z., Tseng, Y., White, M.F., Insulin signaling meets mitochondria in metabolism. Trends Endocrinol. Metab. 21 (2010), 589–598, 10.1016/j.tem.2010.06.005.
32. Cherry, J.D., Olschowka, J.A., O'Banion, M.K., Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J. Neuroinflammation, 11, 2014, 98, 10.1186/1742-2094-11-98.
33. Chiu, S.-L., Chen, C.-M., Cline, H.T., Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron 58 (2008), 708–719, 10.1016/j.neuron.2008.04.014.
34. Choi, J.-Y., Jang, E.-H., Park, C.-S., Kang, J.-H., Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity. Free Radic. Biol. Med. 38 (2005), 806–816, 10.1016/j.freeradbiomed.2004.12.008.
35. Christensen, M., Sparre-Ulrich, A.H., Hartmann, B., Grevstad, U., Rosenkilde, M.M., Holst, J.J., Vilsbøll, T., Knop, F.K., Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes. Int. J. Obes. 39 (2015), 1651–1654, 10.1038/ijo.2015.136.
36. Copps, K.D., Hancer, N.J., Opare-Ado, L., Qiu, W., Walsh, C., White, M.F., Irs1 serine 307 promotes insulin sensitivity in mice. Cell Metab. 11 (2010), 84–92, 10.1016/j.cmet.2009.11.003.
37. De Pablo-Fernández, E., Breen, D.P., Bouloux, P.M., Barker, R.A., Foltynie, T., Warner, T.T., Neuroendocrine abnormalities in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 2016, 10.1136/jnnp-2016-314601 jnnp–2016–314601.
38. De Pablo-Fernandez, E., Sierra-Hidalgo, F., Benito-León, J., Bermejo-Pareja, F., Association between Parkinson's disease and diabetes: data from NEDICES study. Acta Neurol. Scand., 2017, 10.1111/ane.12793.
39. Devaskar, S.U., Giddings, S.J., Rajakumar, P.A., Carnaghi, L.R., Menon, R.K., Zahm, D.S., Insulin gene expression and insulin synthesis in mammalian neuronal cells. J. Biol. Chem. 269 (1994), 8445–8454.
40. Diehl, T., Mullins, R., Kapogiannis, D., Insulin resistance in Alzheimer's disease. Transl. Res. 183 (2017), 26–40, 10.1016/j.trsl.2016.12.005.
41. Drucker, D.J., Philippe, J., Mojsov, S., Chick, W.L., Habener, J.F., Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl. Acad. Sci. U. S. A. 84 (1987), 3434–3438.
42. Drucker, D.J., Sherman, S.I., Gorelick, F.S., Bergenstal, R.M., Sherwin, R.S., Buse, J.B., Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 33 (2010), 428–433, 10.2337/dc09-1499.
43. Duka, T., Duka, V., Joyce, J.N., Sidhu, A., Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J. 23 (2009), 2820–2830, 10.1096/fj.08-120410.
44. Fan, R., Li, X., Gu, X., Chan, J.C.N., Xu, G., Exendin-4 Protects Pancreatic Beta Cells from Human Islet Amyloid Polypeptide-induced Cell Damage: Potential Involvement of AKT and Mitochondria Biogenesis. 2010, 815–824.
45. Foltynie, T., Aviles-Olmos, I., Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinic. Alzheimers. Dement. 10 (2014), S38–S46, 10.1016/j.jalz.2013.12.005.
46. Gallegos, S., Pacheco, C., Peters, C., Opazo, C.M., Aguayo, L.G., Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease. Front. Neurosci., 9, 2015, 59, 10.3389/fnins.2015.00059.
47. Gao, S., Duan, C., Gao, G., Wang, X., Yang, H., Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1/S6K1 signaling. Int. J. Biochem. Cell Biol. 64 (2015), 25–33, 10.1016/j.biocel.2015.03.006.
48. Giuntini, M., Baldacci, F., Del Prete, E., Bonuccelli, U., Ceravolo, R., Diabetes is associated with postural and cognitive domains in Parkinson's disease. Results from a single-center study. Park. Relat. Disord. 20 (2014), 671–672, 10.1016/j.parkreldis.2014.02.016.
49. Goldin, M., Segal, M., Protein kinase C and ERK involvement in dendritic spine plasticity in cultured rodent hippocampal neurons. Eur. J. Neurosci. 17:12 (2003 Jun), 2529–2539.
50. Greene, L.A., Levy, O., Malagelada, C., Akt as a victim, villain and potential hero in Parkinson's disease pathophysiology and treatment. Cell. Mol. Neurobiol. 31 (2011), 969–978, 10.1007/s10571-011-9671-8.
51. Hamilton, A., Patterson, S., Porter, D., Gault, V.A., Holscher, C., Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J. Neurosci. Res. 89 (2011), 481–489, 10.1002/jnr.22565.
52. Harkavyi, A., Abuirmeileh, A., Lever, R., Kingsbury, A.E., Biggs, C.S., Whitton, P.S., Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J. Neuroinflammation, 5, 2008, 19, 10.1186/1742-2094-5-19.
53. Havrankova, J., Roth, J., Brownstein, M., Insulin receptors are widely distributed in the central nervous system of the rat. Nature 272 (1978), 827–829.
54. Heppner, K.M., Kirigiti, M., Secher, A., Paulsen, S.J., Buckingham, R., Pyke, C., Knudsen, L.B., Vrang, N., Grove, K.L., Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology 156 (2015), 255–267, 10.1210/en.2014-1675.
55. Hernandez-Baltazar, D., Mendoza-Garrido, M.E., Martinez-Fong, D., Activation of GSK-3β and caspase-3 occurs in Nigral dopamine neurons during the development of apoptosis activated by a striatal injection of 6-hydroxydopamine. PLoS One, 8, 2013, e70951, 10.1371/journal.pone.0070951.
56. Herschkovitz, A., Liu, Y.-F., Ilan, E., Ronen, D., Boura-Halfon, S., Zick, Y., Common inhibitory serine sites phosphorylated by IRS-1 kinases, triggered by insulin and inducers of insulin resistance. J. Biol. Chem. 282 (2007), 18018–18027, 10.1074/jbc.M610949200.
57. Hill, J.M., Lesniak, M.A., Pert, C.B., Roth, J., Autoradiographic localization of insulin receptors in rat brain: prominence in olfactory and limbic areas. Neuroscience 17 (1986), 1127–1138.
58. Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., Tuomilehto, J., Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 30 (2007), 842–847, 10.2337/dc06-2011.
59. Hunter, K., Hölscher, C., Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci., 13, 2012, 33, 10.1186/1471-2202-13-33.
60. Ibáñez, P., Bonnet, A.-M., Débarges, B., Lohmann, E., Tison, F., Agid, Y., Dürr, A., Brice, A., Pollak, P., Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364 (2004), 1169–1171, 10.1016/S0140-6736(04)17104-3.
61. Irwin, D.J., Lee, V.M.-Y., Trojanowski, J.Q., Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat. Rev. Neurosci. 14 (2013), 626–636, 10.1038/nrn3549.
62. Jha, S.K., Jha, N.K., Kar, R., Ambasta, R.K., Kumar, P., p38 MAPK and PI3K/AKT signalling cascades inParkinson's disease. Int. J. Mol. Cell. Med. 4 (2015), 67–86.
63. Jones, K.T., Woods, C., Zhen, J., Antonio, T., Carr, K.D., Reith, M.E.A., Effects of diet and insulin on dopamine transporter activity and expression in rat caudate-putamen, nucleus accumbens, and midbrain. J. Neurochem. 140 (2017), 728–740, 10.1111/jnc.13930.
64. Kappe, C., Tracy, L.M., Patrone, C., Iverfeldt, K., Sjöholm, Å., GLP-1 secretion by microglial cells and decreased CNS expression in obesity. J. Neuroinflammation, 9, 2012, 276, 10.1186/1742-2094-9-276.
65. Kastin, A.J., Akerstrom, V., Entry of exendin-4 into brain is rapid but may be limited at high doses. Int. J. Obes. Relat. Metab. Disord. 27 (2003), 313–318, 10.1038/sj.ijo.0802206.
66. Khasnavis, S., Jana, A., Roy, A., Mazumder, M., Bhushan, B., Wood, T., Ghosh, S., Watson, R., Pahan, K., Suppression of nuclear factor-κB activation and inflammation in microglia by physically modified saline. J. Biol. Chem. 287 (2012), 29529–29542, 10.1074/jbc.M111.338012.
67. Kim, K.-S., Park, D.H., Wessel, T.C., Song, B., Wagner, J.A., Joh, T.H., A dual role for the cAMP-dependent protein kinase in tyrosine hydroxylase gene expression. Neurobiology 90 (1993), 3471–3475.
68. Kim, S., Moon, M., Park, S., Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J. Endocrinol. 202 (2009), 431–439, 10.1677/JOE-09-0132.
69. Kim, S.R., Ries, V., Cheng, H.-C., Kareva, T., Oo, T.F., Yu, W.H., Duff, K., Kholodilov, N., Burke, R.E., Age and α-synuclein expression interact to reveal a dependence of dopaminergic axons on endogenous Akt/PKB signaling. Neurobiol. Dis. 44 (2011), 215–222, 10.1016/j.nbd.2011.07.003.
70. Kleinridders, A., Cai, W., Cappellucci, L., Ghazarian, A., Collins, W.R., Vienberg, S.G., Pothos, E.N., Kahn, C.R., Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc. Natl. Acad. Sci. U. S. A., 2015, 10.1073/pnas.1500877112.
71. Kuwabara, T., Kagalwala, M.N., Onuma, Y., Ito, Y., Warashina, M., Terashima, K., Sanosaka, T., Nakashima, K., Gage, F.H., Asashima, M., Insulin biosynthesis in neuronal progenitors derived from adult hippocampus and the olfactory bulb. EMBO Mol. Med. 3 (2011), 742–754, 10.1002/emmm.201100177.
72. Lee, C.-C., Huang, C.-C., Wu, M.-Y., Hsu, K.-S., Insulin stimulates postsynaptic density-95 protein translation via the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway. J. Biol. Chem. 280 (2005), 18543–18550, 10.1074/jbc.M414112200.
73. Lee, Y.H., Giraud, J., Davis, R.J., White, M.F., c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J. Biol. Chem. 278 (2003), 2896–2902, 10.1074/jbc.M208359200.
74. Li, Y., Li, L., Hölscher, C., Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases. Rev. Neurosci. 0 (2016), 1–23, 10.1515/revneuro-2016-0018.
75. Li, Y., Perry, T., Kindy, M.S., Harvey, B.K., Tweedie, D., Holloway, H.W., Powers, K., Shen, H., Egan, J.M., Sambamurti, K., Brossi, A., Lahiri, D.K., Mattson, M.P., Hoffer, B.J., Wang, Y., Greig, N.H., GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. PNAS 106 (2009), 1285–1290.
76. Li, Y., Tweedie, D., Mattson, M.P., Holloway, H.W., Greig, N.H., Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J. Neurochem. 113 (2010), 1621–1631, 10.1111/j.1471-4159.2010.06731.x.
77. Li, Z., Zhou, Z., Huang, G., Hu, F., Xiang, Y., He, L., Exendin-4 protects mitochondria from reactive oxygen species induced apoptosis in pancreatic Beta cells. PLoS One, 8, 2013, e76172, 10.1371/journal.pone.0076172.
78. Liu, W., Jalewa, J., Sharma, M., Li, G., Li, L., Hölscher, C., Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neuroscience 303 (2015), 42–50, 10.1016/j.neuroscience.2015.06.054.
79. Lovshin, J.A., Drucker, D.J., Incretin-based therapies for type 2 diabetes mellitus. Nat. Rev. Endocrinol. 5 (2009), 262–269, 10.1038/nrendo.2009.48.
80. Ma, D.-L., Chen, F.-Q., Xu, W.-J., Yue, W.-Z., Yuan, G., Yang, Y., Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice. J. Neurochem., 2015, 10.1111/jnc.13248.
81. Madsbad, S., Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes. Obes. Metab. 18 (2016), 317–332, 10.1111/dom.12596.
82. Mainardi, M., Fusco, S., Grassi, C., Modulation of hippocampal neural plasticity by glucose-related signaling. Neural Plast., 2015, 657928, 10.1155/2015/657928.
83. Manigault, K., Thurston, M.M., Liraglutide: a glucagon-like Peptide-1 agonist for chronic weight management. Consult. Pharm. 31 (2016), 685–697, 10.4140/TCP.n.2016.685.
84. Mann, K.V., Raskin, P., Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes. Diabetes. Metab. Syndr. Obes. 7 (2014), 229–239, 10.2147/DMSO.S35331.
85. Marciniak, E., Leboucher, A., Caron, E., Ahmed, T., Tailleux, A., Dumont, J., Issad, T., Gerhardt, E., Pagesy, P., Vileno, M., Bournonville, C., Hamdane, M., Bantubungi, K., Lancel, S., Demeyer, D., Eddarkaoui, S., Vallez, E., Vieau, D., Humez, S., Faivre, E., Grenier-Boley, B., Outeiro, T.F., Staels, B., Amouyel, P., Balschun, D., Buee, L., Blum, D., Tau deletion promotes brain insulin resistance. J. Exp. Med., 214, 2017.
86. Martin, F.L., Williamson, S.J.M., Paleologou, K.E., Allsop, D., El-Agnaf, O.M.A., Alpha-synuclein and the pathogenesis of Parkinson's disease. Protein Pept. Lett. 11 (2004), 229–237.
87. Moloney, A.M., Griffin, R.J., Timmons, S., O'Connor, R., Ravid, R., O'Neill, C., Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 31 (2010), 224–243, 10.1016/j.neurobiolaging.2008.04.002.
88. Mora, P.F., Johnson, E.L., Cardiovascular outcome trials of the incretin-based therapies: what do we know so far?. Endocr. Pract. 23 (2017), 89–99, 10.4158/EP161481.RA.
89. Moroo, I., Yamada, T., Makino, H., Tooyama, I., McGeer, P.L., McGeer, E.G., Hirayama, K., Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease. Acta Neuropathol. 87:4 (1994), 343–348.
90. Morris, J.K., Bomhoff, G.L., Gorres, B.K., Davis, V.A., Kim, J., Lee, P.-P., Brooks, W.M., Gerhardt, G.A., Geiger, P.C., Stanford, J.A., Insulin resistance impairs nigrostriatal dopamine function. Exp. Neurol. 231 (2011), 171–180, 10.1016/j.expneurol.2011.06.005.
91. Morris, J.K., Bomhoff, G.L., Stanford, J.A., Geiger, P.C., Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet. AJP Regul. Integr. Comp. Physiol. 299 (2010), R1082–R1090, 10.1152/ajpregu.00449.2010.
92. Morris, J.K., Zhang, H., Gupte, A.A., Bomhoff, G.L., Stanford, J.A., Geiger, P.C., Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease. Brain Res. 1240 (2008), 185–195, 10.1016/j.brainres.2008.08.089.
93. Moussaud, S., Jones, D.R., Moussaud-Lamodière, E.L., Delenclos, M., Ross, O.A., McLean, P.J., Alpha-synuclein and tau: teammates in neurodegeneration?. Mol. Neurodegener., 9, 2014, 43, 10.1186/1750-1326-9-43.
94. Müssig, K., Staiger, H., Fiedler, H., Moeschel, K., Beck, A., Kellerer, M., Häring, H.-U., Shp2 is required for protein kinase C-dependent phosphorylation of serine 307 in insulin receptor Substrate-1. J. Biol. Chem. 280 (2005), 32693–32699, 10.1074/jbc.M506549200.
95. Nagao, M., Hayashi, H., Glycogen synthase kinase-3beta is associated with Parkinson's disease. Neurosci. Lett. 449 (2009), 103–107, 10.1016/j.neulet.2008.10.104.
96. Nassar, N.N., Al-Shorbagy, M.Y., Arab, H.H., Abdallah, D.M., Saxagliptin: a novel antiparkinsonian approach. Neuropharmacology 89 (2015), 308–317, 10.1016/j.neuropharm.2014.10.007.
97. Palacios, N., Gao, X., McCullough, M.L., Jacobs, E.J., Patel, A.V., Mayo, T., Schwarzschild, M.A., Ascherio, A., Obesity, diabetes, and risk of Parkinson's disease. Mov. Disord. 26 (2011), 2253–2259, 10.1002/mds.23855.
98. Park, M.H., Kim, D.H., Lee, E.K., Kim, N.D., Im, D.S., Lee, J., Yu, B.P., Chung, H.Y., Age-related inflammation and insulin resistance: a review of their intricate interdependency. Arch. Pharm. Res. 37 (2014), 1507–1514, 10.1007/s12272-014-0474-6.
99. Parkes, D.G., Mace, K.F., Trautmann, M.E., Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. Expert Opin. Drug Discov. 8 (2013), 219–244, 10.1517/17460441.2013.741580.
100. Perruolo, G., Viggiano, D., Fiory, F., Cassese, A., Nigro, C., Liotti, A., Miele, C., Beguinot, F., Formisano, P., Parkinson-like phenotype in insulin-resistant PED/PEA-15 transgenic mice. Sci. Rep., 6, 2016, 29967, 10.1038/srep29967.
101. Perry, T., Lahiri, D.K., Chen, D., Zhou, J., Shaw, K.T.Y., Egan, J.M., Greig, N.H., A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther. 300 (2002), 958–966.
102. Prasad-Reddy, L., Isaacs, D., A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context, 4, 2015, 212283, 10.7573/dic.212283.
103. Rannikko, E.H., Weber, S.S., Kahle, P.J., Exogenous α-synuclein induces toll-like receptor 4 dependent inflammatory responses in astrocytes. BMC Neurosci., 16, 2015, 57, 10.1186/s12868-015-0192-0.
104. Reagan, L.P., Diabetes as a chronic metabolic stressor: causes, consequences and clinical complications. Exp. Neurol. 233 (2012), 68–78, 10.1016/j.expneurol.2011.02.004.
105. Reddy, I.A., Pino, J.A., Weikop, P., Osses, N., Sørensen, G., Bering, T., Valle, C., Bluett, R.J., Erreger, K., Wortwein, G., Reyes, J.G., Graham, D., Stanwood, G.D., Hackett, T.A., Patel, S., Fink-Jensen, A., Torres, G.E., Galli, A., Glucagon-like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels. Transl. Psychiatry, 6, 2016, e809, 10.1038/tp.2016.86.
106. Reiner, D.J., Mietlicki-Baase, E.G., McGrath, L.E., Zimmer, D.J., Bence, K.K., Sousa, G.L., Konanur, V.R., Krawczyk, J., Burk, D.H., Kanoski, S.E., Hermann, G.E., Rogers, R.C., Hayes, M.R., Astrocytes regulate GLP-1 receptor-mediated effects on energy balance. J. Neurosci. 36 (2016), 3531–3540, 10.1523/JNEUROSCI.3579-15.2016.
107. Schapira, A.H.V., Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 7 (2008), 97–109, 10.1016/S1474-4422(07)70327-7.
108. Schernhammer, E., Hansen, J., Rugbjerg, K., Wermuth, L., Ritz, B., Diabetes and the risk of developing Parkinson's disease in Denmark. Diabetes Care 34 (2011), 1102–1108, 10.2337/dc10-1333.
109. Seufert, J., Gallwitz, B., The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes. Obes. Metab. 16 (2014), 673–688, 10.1111/dom.12251.
110. Sharma, S.K., Chorell, E., Steneberg, P., Vernersson-Lindahl, E., Edlund, H., Wittung-Stafshede, P., Insulin-degrading enzyme prevents α-synuclein fibril formation in a nonproteolytical manner. Sci. Rep., 5, 2015, 12531, 10.1038/srep12531.
111. Sharma, S.K., Chorell, E., Wittung-Stafshede, P., Insulin-degrading enzyme is activated by the C-terminus of α-synuclein. Biochem. Biophys. Res. Commun. 466 (2015), 192–195, 10.1016/j.bbrc.2015.09.002.
112. Shiraishi, D., Fujiwara, Y., Komohara, Y., Mizuta, H., Takeya, M., Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation. Biochem. Biophys. Res. Commun. 425 (2012), 304–308, 10.1016/j.bbrc.2012.07.086.
113. Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A., Hanson, M., Maraganore, D., Adler, C., Cookson, M.R., Muenter, M., Baptista, M., Miller, D., Blancato, J., Hardy, J., Gwinn-Hardy, K., Alpha synuclein locus triplication causes Parkinson's disease. Science, 80(302), 2003, 10.1126/science.1090278 841–841.
114. Spielman, L.J., Gibson, D.L., Klegeris, A., Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors. Eur. J. Cell Biol. 96 (2017), 240–253, 10.1016/j.ejcb.2017.03.004.
115. Stouffer, M.A., Woods, C.A., Patel, J.C., Lee, C.R., Witkovsky, P., Bao, L., Machold, R.P., Jones, K.T., de Vaca, S.C., Reith, M.E.A., Carr, K.D., Rice, M.E., Insulin enhances striatal dopamine release by activating cholinergic interneurons and thereby signals reward. Nat. Commun., 6, 2015, 8543, 10.1038/ncomms9543.
116. Sun, J., Xia, W., Cai, R., Wang, P., Huang, R., Sun, H., Tian, S., Dong, X., Wang, S., Serum insulin degrading enzyme level and other factors in type 2 diabetic patients with mild cognitive impairment. Curr. Alzheimer Res. 13 (2016), 1337–1345.
117. Sun, Y., Chang, Y.-H., Chen, H.-F., Su, Y.-H., Su, H.-F., Li, C.-Y., Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications. Diabetes Care 35 (2012), 1047–1049, 10.2337/dc11-1511.
118. Svenningsson, P., Wirdefeldt, K., Yin, L., Fang, F., Markaki, I., Efendic, S., Ludvigsson, J.F., Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study. Mov. Disord., 2016, 10.1002/mds.26734.
119. Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K.P., Stucky, A., Fuino, R.L., Kawaguchi, K.R., Samoyedny, A.J., Wilson, R.S., Arvanitakis, Z., Schneider, J.A., Wolf, B.A., Bennett, D.A., Trojanowski, J.Q., Arnold, S.E., Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest 122 (2012), 1316–1338, 10.1172/JCI59903.
120. Teramoto, S., Miyamoto, N., Yatomi, K., Tanaka, Y., Oishi, H., Arai, H., Hattori, N., Urabe, T., Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J. Cereb. Blood Flow. Metab. 31 (2011), 1696–1705, 10.1038/jcbfm.2011.51.
121. Tews, D., Lehr, S., Hartwig, S., Osmers, A., Paslack, W., Eckel, J., Anti-apoptotic action of exendin-4 in INS-1 beta cells: comparative protein pattern analysis of isolated mitochondria. Horm. Metab. Res. 41 (2009), 294–301, 10.1055/s-0028-1105911.
122. Tokutake, T., Kasuga, K., Yajima, R., Sekine, Y., Tezuka, T., Nishizawa, M., Ikeuchi, T., Hyperphosphorylation of Tau induced by naturally secreted amyloid-β at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3β signaling pathway. J. Biol. Chem. 287 (2012), 35222–35233, 10.1074/jbc.M112.348300.
123. Trapp, S., Cork, S.C., Abbas, T., Faivre, E., Holscher, C., Abbott, S., Stornetta, R., Socolovsky, C., West, G., Guyenet, P., Abdelsalam, R., Safar, M., Alhadeff, A., Baird, J., Swick, J., Hayes, M., Grill, H., Alhadeff, A., Rupprecht, L., Hayes, M., Asarian, L., Baraboi, E., Smith, P., Ferguson, A., Richard, D., Barrera, J., Jones, K., Herman, J., D'Alessio, D., Woods, S., Seeley, R., Beiroa, D., Imbernon, M., Gallego, R., Senra, A., Herranz, D., Villarroya, F., Serrano, M., Ferno, J., Salvador, J., Escalada, J., Dieguez, C., Lopez, M., Fruhbeck, G., Nogueiras, R., Cabou, C., Campistron, G., Marsollier, N., Leloup, C., Cruciani-Guglielmacci, C., Penicaud, L., Drucker, D., Magnan, C., Burcelin, R., Felice, F., De Dickson, S., Shirazi, R., Hansson, C., Bergquist, F., Nissbrandt, H., Skibicka, K., Dossat, A., Diaz, R., Gallo, L., Panagos, A., Kay, K., Williams, D., Dossat, A., Lilly, N., Kay, K., Williams, D., Drucker, D., During, M., Cao, L., Zuzga, D., Francis, J., Fitzsimons, H., Jiao, X., Bland, R., Klugmann, M., Banks, W., Drucker, D., Haile, C., Egecioglu, E., Engel, J., Jerlhag, E., Egecioglu, E., Steensland, P., Fredriksson, I., Feltmann, K., Engel, J., Jerlhag, E., Erreger, K., Davis, A., Poe, A., Greig, N., Stanwood, G., Galli, A., Flint, A., Raben, A., Astrup, A., Holst, J., Gault, V., Holscher, C., Gilman, C., Perry, T., Furukawa, K., Grieg, N., Egan, J., Mattson, M., Goldstone, A., Mercer, J., Gunn, I., Moar, K., Edwards, C., Rossi, M., Howard, J., Rasheed, S., Turton, M., Small, C., Heath, M., O'Shea, D., Steere, J., Meeran, K., Ghatei, M., Hoggard, N., Bloom, S., Goldstone, A., Morgan, I., Mercer, J., Morgan, D., Moar, K., Ghatei, M., Bloom, S., Graham, D., Erreger, K., Galli, A., Stanwood, G., Grill, H., Carmody, J., Sadacca, L.A., Williams, D., Kaplan, J., Gutzwiller, J., Goke, B., Drewe, J., Hildebrand, P., Ketterer, S., Handschin, D., Winterhalder, R., Conen, D., Beglinger, C., Halford, J., Boyland, E., Blundell, J., Kirkham, T., Harrold, J., Hansen, H., Fabricius, K., Barkholt, P., Niehoff, M., Morley, J., Jelsing, J., Pyke, C., Knudsen, L.B., Farr, S., Vrang, N., Hayes, M., Bradley, L., Grill, H., Hayes, M., Kanoski, S., Jonghe, B., De Leichner, T., Alhadeff, A., Fortin, S., Arnold, M., Langhans, W., Grill, H., Hayes, M., Skibicka, K., Grill, H., Heppner, K., Kirigiti, M., Secher, A., Paulsen, S., Buckingham, R., Pyke, C., Knudsen, L., Vrang, N., Grove, K., Hisadome, K., Reimann, F., Gribble, F., Trapp, S., Hisadome, K., Reimann, F., Gribble, F., Trapp, S., Holmes, G., Browning, K., Tong, M., Qualls-Creekmore, E., Travagli, R., Hsu, T., Hahn, J., Konanur, V., Lam, A., Kanoski, S., Huo, L., Gamber, K., Grill, H., Bjorbaek, C., Jin, S., Han, V., Simmons, J., Towle, A., Lauder, J., Lund, P., Jun, L., Showalter, A., Ali, N., Dai, F., Ma, W., Coskun, T., Ficorilli, J., Wheeler, M., Michael, M., Sloop, K., Kanoski, S., Rupprecht, L., Fortin, S., Jonghe, B., De Hayes, M., Kastin, A., Akerstrom, V., Pan, W., Kinzig, K., D'Alessio, D., Seeley, R., Knauf, C., Cani, P., Ait-Belgnaoui, A., Benani, A., Dray, C., Cabou, C., Colom, A., Uldry, M., Rastrelli, S., Sabatier, E., Godet, N., Waget, A., Penicaud, L., Valet, P., Burcelin, R., Knauf, C., Cani, P., Perrin, C., Iglesias, M., Maury, J., Bernard, E., Benhamed, F., Gremeaux, T., Drucker, D., Kahn, C., Girard, J., Tanti, J., Delzenne, N., Postic, C., Burcelin, R., Kopf, B., Langhans, W., Geary, N., Asarian, L., Korol, S., Jin, Z., Babateen, O., Birnir, B., Kreisler, A., Davis, E., Rinaman, L., Lam, D., Garfield, A., Marston, O., Shaw, J., Heisler, L., Langhans, W., Larsen, P., Tang-Christensen, M., Holst, J., Orskov, C., Lennox, R., Flatt, P., Gault, V., Liu, W., Jalewa, J., Sharma, M., Li, G., Li, L., Holscher, C., Llewellyn-Smith, I., Gnanamanickam, G., Reimann, F., Gribble, F., Trapp, S., Llewellyn-Smith, I., Marina, N., Manton, R., Reimann, F., Gribble, F., Trapp, S., Llewellyn-Smith, I., Reimann, F., Gribble, F., Trapp, S., Lockie, S., Andrews, Z., Lockie, S., Heppner, K., Chaudhary, N., Chabenne, J., Morgan, D., Veyrat-Durebex, C., Ananthakrishnan, G., Rohner-Jeanrenaud, F., Drucker, D., DiMarchi, R., Rahmouni, K., Oldfield, B., Tschop, M., Perez-Tilve, D., Maniscalco, J., Rinaman, L., Manning, S., Pucci, A., Batterham, R., Marina, N., Abdala, A., Trapp, S., Li, A., Nattie, E., Hewinson, J., Smith, J., Paton, J., Gourine, A., McMahon, L., Wellman, P., Merchenthaler, I., Lane, M., Shughrue, P., Mietlicki-Baase, E., Ortinski, P., Reiner, D., Sinon, C., McCutcheon, J., Pierce, R., Roitman, M., Hayes, M., Mietlicki-Baase, E., Ortinski, P., Rupprecht, L., Olivos, D., Alhadeff, A., Pierce, R., Hayes, M., Morris, J., Pow, D., Morris, J., Vidoni, E., Honea, R., Burns, J., neuroimaging, I.A., disease Morrison, S., Nakamura, K., Madden, C., Oka, J., Goto, N., Kameyama, T., Orskov, C., Poulsen, S., Moller, M., Holst, J., Palouzier-Paulignan, B., Lacroix, M., Aime, P., Baly, C., Caillol, M., Congar, P., Julliard, A., Tucker, K., Fadool, D., Parker, H., Adriaenssens, A., Rogers, G., Richards, P., Koepsell, H., Reimann, F., Gribble, F., Plamboeck, A., Veedfald, S., Deacon, C., Hartmann, B., Wettergren, A., Svendsen, L., Meisner, S., Hovendahl, C., Vilsboll, T., Knop, F., Holst, J., Punjabi, M., Arnold, M., Ruttimann, E., Graber, M., Geary, N., Pacheco-Lopez, G., Langhans, W., Richard, J., Anderberg, R., Goteson, A., Gribble, F., Reimann, F., Skibicka, K., Richard, J., Farkas, I., Anesten, F., Anderberg, R., Dickson, S., Gribble, F., Reimann, F., Jansson, J., Liposits, Z., Skibicka, K., Richards, P., Parker, H., Adriaenssens, A., Hodgson, J., Cork, S., Trapp, S., Gribble, F., Reimann, F., Rinaman, L., Fonseca, F.R., de Navarro, M., Alvarez, E., Roncero, I., Chowen, J., Maestre, O., Gomez, R., Munoz, R., Eng, J., Blazquez, E., Ronveaux, C., Tome, D., Raybould, H., Ruttimann, E., Arnold, M., Hillebrand, J., Geary, N., Langhans, W., Sandoval, D., Bagnol, D., Woods, S., D'Alessio, D., Seeley, R., Sandoval, D., D'Alessio, D., Secher, A., Jelsing, J., Baquero, A., Hecksher-Sorensen, J., Cowley, M., Dalboge, L., Hansen, G., Grove, K., Pyke, C., Raun, K., Schaffer, L., Tang-Christensen, M., Verma, S., Witgen, B., Vrang, N., Knudsen, L.B., Shimizu, I., Hirota, M., Ohboshi, C., Shima, K., Shirazi, R., Dickson, S., Skibicka, K., Skibicka, K., Stern, J., Tang-Christensen, M., Larsen, P., Goke, R., Fink-Jensen, A., Jessop, D., Moller, M., Sheikh, S., Tauchi, M., Zhang, R., D'Alessio, D., Stern, J., Herman, J., Thiele, T., Dijk, G., Van Campfield, L., Smith, F., Burn, P., Woods, S., Bernstein, I., Seeley, R., Turton, M., O'Shea, D., Gunn, I., Beak, S., Edwards, C., Meeran, K., Choi, S., Taylor, G., Heath, M., Lambert, P., Wilding, J., Smith, D., Ghatei, M., Herbert, J., Bloom, S., Pol, A., van den Dijk, G., van Thiele, T., Vrang, N., Grove, K., Vrang, N., Hansen, M., Larsen, P., Tang-Christensen, M., Vrang, N., Phifer, C., Corkern, M., Berthoud, H., Wan, S., Coleman, F., Travagli, R., Williams, D., Baskin, D., Schwartz, M., Williams, D., Baskin, D., Schwartz, M., Xu, W., Yang, Y., Yuan, G., Zhu, W., Ma, D., Hu, S., Yamamoto, H., Kishi, T., Lee, C., Choi, B., Fang, H., Hollenberg, A., Drucker, D., Elmquist, J., Yamamoto, H., Lee, C., Marcus, J., Williams, T., Overton, J., Lopez, M., Hollenberg, A., Baggio, L., Saper, C., Drucker, D., Elmquist, J., Yoshino, Y., Ishisaka, M., Tsujii, S., Shimazawa, M., Hara, H., Zhang, J., Ritter, R., Zhao, S., Kanoski, S., Yan, J., Grill, H., Hayes, M., Zheng, H., Cai, L., Rinaman, L., Zheng, H., Stornetta, R., Agassandian, K., Rinaman, L., PPG neurons of the lower brain stem and their role in brain GLP-1 receptor activation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 309 (2015), R795–R804, 10.1152/ajpregu.00333.2015.
124. Tremblay, F., Brule, S., Hee Um, S., Li, Y., Masuda, K., Roden, M., Sun, X.J., Krebs, M., Polakiewicz, R.D., Thomas, G., Marette, A., Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc. Natl. Acad. Sci. 104 (2007), 14056–14061, 10.1073/pnas.0706517104.
125. Ventorp, F., Bay-Richter, C., Nagendra, A.S., Janelidze, S., Matsson, V.S., Lipton, J., Nordström, U., Westrin, Åsa, Brundin, P., Brundin, L., Exendin-4 treatment improves LPS-induced depressive-like behavior without affecting pro-inflammatory cytokines. J. Park. Dis. 7 (2017), 263–273, 10.3233/JPD-171068.
126. Wahlqvist, M.L., Lee, M.-S., Hsu, C.-C., Chuang, S.-Y., Lee, J.-T., Tsai, H.-N., Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort. Park. Relat. Disord. 18 (2012), 753–758, 10.1016/j.parkreldis.2012.03.010.
127. Wang, L., Zhai, Y.-Q., Xu, L.-L., Qiao, C., Sun, X.-L., Ding, J.-H., Lu, M., Hu, G., Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice. Exp. Neurol. 251 (2014), 22–29, 10.1016/j.expneurol.2013.11.001.
128. Wang, M.-D., Huang, Y., Zhang, G.-P., Mao, L., Xia, Y.-P., Mei, Y.-W., Hu, B., Exendin-4 improved rat cortical neuron survival under oxygen/glucose deprivation through PKA pathway. Neuroscience 226 (2012), 388–396, 10.1016/j.neuroscience.2012.09.025.
129. Wang, Q., Li, L., Xu, E., Wong, V., Rhodes, C., Brubaker, P.L., Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 47 (2004), 478–487, 10.1007/s00125-004-1327-5.
130. Watson, G.S., Peskind, E.R., Asthana, S., Purganan, K., Wait, C., Chapman, D., Schwartz, M.W., Plymate, S., Craft, S., Insulin increases CSF Abeta42 levels in normal older adults. Neurology 60 (2003), 1899–1903.
131. Wills, J., Jones, J., Haggerty, T., Duka, V., Joyce, J.N., Sidhu, A., Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp. Neurol. 225 (2010), 210–218, 10.1016/j.expneurol.2010.06.017.
132. Xu, Q., Park, Y., Huang, X., Hollenbeck, A., Blair, A., Schatzkin, A., Chen, H., Diabetes and risk of Parkinson's disease. Diabetes Care 34 (2011), 910–915, 10.2337/dc10-1922.
133. Xu, W., Yang, Y., Yuan, G., Zhu, W., Ma, D., Hu, S., Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes. J. Investig. Med. 63 (2015), 267–272, 10.1097/JIM.0000000000000129.
134. Yang, Y., Zhang, J., Ma, D., Zhang, M., Hu, S., Shao, S., Gong, C.-X., Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes. J. Alzheimers. Dis. 37 (2013), 637–648, 10.3233/JAD-130491.
135. Yao, W.-D., Gainetdinov, R.R., Arbuckle, M.I., Sotnikova, T.D., Cyr, M., Beaulieu, J.-M., Torres, G.E., Grant, S.G.N., Caron, M.G., Identification of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity. Neuron 41 (2004), 625–638.
136. Yarchoan, M., Toledo, J.B., Lee, E.B., Arvanitakis, Z., Kazi, H., Han, L.-Y., Louneva, N., Lee, V.M.-Y., Kim, S.F., Trojanowski, J.Q., Arnold, S.E., Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies. Acta Neuropathol. 128 (2014), 679–689, 10.1007/s00401-014-1328-5.
137. Zhan, Y., Sun, H., Chen, H., Zhang, H., Sun, J., Zhang, Z., Cai, D., Glucagon-like peptide-1 (GLP-1) protects vascular endothelial cells against advanced glycation end products (AGEs)-induced apoptosis. Med. Sci. Monit. 18 (2012), BR286–B291.
138. Zhang, H., Meng, J., Li, X., Zhou, S., Qu, D., Wang, N., Jia, M., Ma, X., Luo, X., Pro-GLP-1, a Pro-drug of GLP-1, is neuroprotective in cerebral ischemia. Eur. J. Pharm. Sci. 70 (2015), 82–91, 10.1016/j.ejps.2015.01.010.
139. Zhang, Y., Xia, Z., Liu, J., Yin, F., Cell signaling mechanisms by which geniposide regulates insulin- degrading enzyme expression in primary cortical neurons. CNS Neurol. Disord. Drug Targets 14 (2015), 370–377.
140. Zhao, W.-Q., Townsend, M., Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim. Biophys. Acta 1792 (2009), 482–496, 10.1016/j.bbadis.2008.10.014.
141. Zhou, H., Li, D., Shi, C., Xin, T., Yang, J., Zhou, Y., Hu, S., Tian, F., Wang, J., Chen, Y., Effects of Exendin-4 on bone marrow mesenchymal stem cell proliferation, migration and apoptosis in vitro. Sci. Rep., 5, 2015, 12898, 10.1038/srep12898.